TNXP

Tonix Pharmaceuticals Holding Corp.

TNXP | $0.1554 -2.88% -2.37% 240K

(0.0% 1d) (-51.2% 1m) (-94.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (24.5% volume)
Earnings Calendar: 2022-11-07
Market Cap: $ 13,129,880
http://www.tonixpharma.com
Sec Filling | Patents | 16 employees

(United States) Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

vaccine fibromyalgia cancer pancreatic

add to watch list Paper trade email alert is off

Press-releases

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
TNXP | $0.1554 -2.88% -2.37% 240K

Health Technology

| -15.75% | O: 0.05% H: 0.63% C: 0.32%
year pharmaceuticals financial results

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Published: 2024-03-28 (Crawled : 13:30) - globenewswire.com
TNXP | $0.1554 -2.88% -2.37% 240K

Health Technology

| -51.06% | O: -0.58% H: 5.85% C: -42.77%
million direct offering pharmaceuticals

Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1554 -2.88% -2.37% 240K

Health Technology

| -53.76% | O: 0.0% H: 0.03% C: -5.2%
tnx-2900 fda rare disease treatment pharmaceuticals designation

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1554 -2.88% -2.37% 240K

Health Technology

| -55.32% | O: 0.53% H: 1.58% C: -4.31%
presentation oxytocin pharmaceuticals spring meeting

Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1554 -2.88% -2.37% 240K

Health Technology

| -53.93% | O: 3.66% H: 2.78% C: -0.53%
management fibromyalgia contract pharmaceuticals commercial

Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1554 -2.88% -2.37% 240K

Health Technology

| -52.02% | O: 4.8% H: 6.7% C: -0.63%
company expected pharmaceuticals

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1554 -2.88% -2.37% 240K

Health Technology